Nexa Diagnostics: A Useful-Life Extension That Arrives With a Launch Delay
Nexa Diagnostics prepares IFRS statements. In 20X3 it capitalized $48 million of development costs for a sepsis assay, bringing the gross development asset to $112 million. Because the assay's commercial launch slipped by 18 months, management extended the amortization period from five to eight years and recognized no impairment. The change cut 20X3 amortization from $12 million to $9 million. Nexa reported pre-tax income of $72 million, net income of $57.6 million (20% tax), and operating cash flow of $31 million. Development spend is Nexa's largest cash outflow after payroll, and three listed peers expense all research and development. The credit agreement tests leverage on EBITDA, which is flattered because capitalized development never passes through the income statement. Management argues the extension is justified because regulators have indicated the assay will be approved, and because a competitor's similar product has an eight-year commercial life.
1. Assess whether the useful-life extension and the decision not to impair are defensible under IFRS, and identify the evidence that would settle the question.
Read the worked answer
Framework. Under IAS 38, capitalised development costs are amortised over their expected useful life, and a revision to that life is a change in accounting estimate under IAS 8, applied prospectively. So the mechanics are permitted. The question is whether the estimate is supported, and whether impairment indicators exist.
Why the extension looks unsupported.
- The trigger event is a delay. An 18-month slip compresses, not lengthens, the window in which the asset can earn returns. Absent a patent term, exclusivity extension, or contractual commitment, moving from five to eight years is internally inconsistent with the news that prompted it.
- An intangible not yet available for use must be tested for impairment annually under IAS 36 regardless of indicators, and a launch delay, regulatory uncertainty and competitor entry are all classic indicators.
- 'Regulators have indicated approval' is not approval. A competitor's commercial life says nothing about this molecule's label, pricing or reimbursement.
- The timing is a red flag: the estimate change adds exactly $3 million to pre-tax income in the same period the delay was disclosed.
Evidence that would settle it. The approval date and label scope; reimbursement or hospital contract commitments; probability-weighted cash-flow forecasts and the pre-tax discount rate used; and the sensitivity of value in use to a further 12-month delay. If value in use at a 12-month delay still exceeds carrying amount, the extension and non-impairment are defensible. If not, an impairment charge is required before any life extension is debated.
2. Quantify the effect on 20X3 pre-tax income of (i) the amortization change and (ii) expensing development costs as incurred, and explain the asymmetric effect on EBITDA and on the leverage covenant.
Read the worked answer
(i) Amortization change.
- Amortization at five years: $12m. At eight years: $9m. Pre-tax income is higher by $3m.
- After 20% tax, net income is higher by $2.4m, or 4.2% of the reported $57.6m. Small in absolute terms but large relative to a $72m pre-tax base and exactly offsetting an otherwise short earnings year.
(ii) Expensing as incurred.
- Remove the $48m capitalization from the balance sheet and put it through the income statement; the $9m amortization disappears.
- Adjusted pre-tax income = 72 − 48 + 9 = $33m; adjusted net income = $26.4m, roughly 54% below reported.
- The remaining net book value would also fall out of equity, lowering ROE and raising asset turnover.
The covenant asymmetry is the key insight. The life change moves net income but leaves EBITDA untouched, because amortization is added back in arriving at EBITDA. Expensing does the opposite: it cuts EBITDA by the full $48m, since the item never enters operating profit and no amortization add-back offsets it. A covenant that tests debt/EBITDA therefore looks comfortable under the capitalizing policy and deteriorates sharply under the peer policy, even though cash flow is identical. An analyst who adjusts earnings for comparability must adjust covenant EBITDA on the same basis, or the leverage assessment will be wrong in the wrong direction.
3. Operating cash flow of $31m against net income of $57.6m: what does the cash flow statement add to the analysis, and how should the analyst restate the company for peer comparison?
Read the worked answer
Cash conversion. CFO/net income of 0.54 is weak and points to the same conclusion as the capitalization policy: reported profit is not being converted into cash. Capitalizing development moves the spend into investing outflows, which flatters CFO and any price/CFO multiple relative to peers who expense. Free cash flow (CFO less capex, including capitalized development) is more comparable, but even FCF leaves the development spend outside the operating profitability measure that peers report.
Restatement for comparability.
- Treat the $48m of 20X3 development spend as an operating expense; reverse the $9m amortization; tax-effect the difference at 20%.
- Restate EBITDA downward by the same $48m, and disclose the adjusted leverage alongside the covenant figure.
- Because capitalised development is a recurring, cash-consuming investment rather than a one-off, do not treat it as a non-recurring item to be added back.
Analytical conclusion. The analyst should present both the company's view and the adjusted view, flag the estimate change as a quality-of-earnings signal, and monitor three things: whether impairment testing is disclosed with discount rate and cash-flow assumptions; whether the amortization profile changes again near the next reporting date; and whether the covenant headroom depends on the capitalization policy continuing. A company whose compliance with a leverage test rests on an accounting policy choice rather than on cash generation carries refinancing risk that the reported multiple conceals.